McCollum Gary W, Rajaratnam Veera S, Bullard Lawrence E, Yang Rong, Penn John S
Department of Ophthalmology and Visual Sciences, Vanderbilt University School of Medicine, 8016 Medical Center East, Nashville, TN 37232-8808, USA.
Exp Eye Res. 2004 May;78(5):987-95. doi: 10.1016/j.exer.2003.12.008.
The pathogenesis of retinopathy of prematurity involves dysregulated angiogenesis resulting in pre-retinal growth of new vessels. Inhibition of tyrosine kinase-dependent pro-angiogenic signals may provide a rational therapeutic approach to the reduction of pre-retinal neovascularization. Vascular endothelial growth factor stimulates endothelial cell mitogenesis, differentiation and migration, by binding and activating the receptor tyrosine kinases vascular endothelial growth factor receptor-1 and vascular endothelial growth factor receptor-2. One of the vascular endothelial growth factor receptor substrates implicated in vascular endothelial growth factor signal transduction is c-Src. The ability of herbimycin A, a c-Src-selective tyrosine kinase inhibitor, to inhibit vascular endothelial growth factor-induced bovine retinal microvascular endothelial cell proliferation and tube formation was investigated. The ability of the compound to inhibit pathologic angiogenesis was tested in a rat model of retinopathy of prematurity. Exposure of neonatal rats to oxygen concentrations cycling between 10 and 50% induced severe pre-retinal neovascularization in all rats. Some of the eyes of these variable oxygen-exposed rats were herbimycin A-injected or vehicle-injected 1 or 3 days post-oxygen exposure while some eyes were non-injected. All rats were sacrificed for assessment 6 days post-exposure. Herbimycin A inhibited both vascular endothelial growth factor-induced bovine retinal microvascular endothelial cell proliferation and capillary tube formation in a dose-dependent manner. Injection of herbimycin A into oxygen-treated rats 1 day post-oxygen exposure produced a 63% decrease in pre-retinal neovascularization relative to vehicle (P = 0.0029). There was a 41% decrease in pre-retinal neovascularization in herbimycin-injected eyes relative to vehicle-injected eyes 3 days post-oxygen (P = 0.031). Pre-retinal neovascularization was reduced in vehicle-injected eyes relative to non-injected eyes at both injection times. There were no significant differences in retinal vascular area between any of the experimental groups. Based on the results of this study, herbimycin A inhibits endothelial cell proliferation and tube formation at non-toxic concentrations and reduces pre-retinal neovascularization in a rat model of retinopathy of prematurity. Reduction of angiogenesis by the inhibition of tyrosine kinase activity may be a viable route to the development of effective chemotherapies applicable to eye disease.
早产儿视网膜病变的发病机制涉及血管生成失调,导致视网膜前新生血管生长。抑制酪氨酸激酶依赖性促血管生成信号可能为减少视网膜前新生血管形成提供一种合理的治疗方法。血管内皮生长因子通过结合并激活受体酪氨酸激酶血管内皮生长因子受体-1和血管内皮生长因子受体-2,刺激内皮细胞有丝分裂、分化和迁移。参与血管内皮生长因子信号转导的血管内皮生长因子受体底物之一是c-Src。研究了c-Src选择性酪氨酸激酶抑制剂赫曲霉素A抑制血管内皮生长因子诱导的牛视网膜微血管内皮细胞增殖和管腔形成的能力。在早产儿视网膜病变大鼠模型中测试了该化合物抑制病理性血管生成的能力。将新生大鼠暴露于10%至50%循环变化的氧浓度下,所有大鼠均出现严重的视网膜前新生血管形成。在这些暴露于不同氧浓度的大鼠中,部分大鼠在氧暴露后1天或3天,其一只眼睛注射赫曲霉素A,另一只眼睛注射赋形剂,还有部分眼睛未注射。所有大鼠在暴露后6天处死进行评估。赫曲霉素A以剂量依赖性方式抑制血管内皮生长因子诱导的牛视网膜微血管内皮细胞增殖和毛细血管管腔形成。在氧暴露后1天向经氧处理的大鼠注射赫曲霉素A,相对于注射赋形剂的大鼠,视网膜前新生血管形成减少了63%(P = 0.0029)。在氧暴露后3天,注射赫曲霉素A的眼睛相对于注射赋形剂的眼睛,视网膜前新生血管形成减少了41%(P = 0.031)。在两个注射时间点,相对于未注射的眼睛,注射赋形剂的眼睛视网膜前新生血管形成均减少。各实验组之间视网膜血管面积无显著差异。基于本研究结果,赫曲霉素A在无毒浓度下抑制内皮细胞增殖和管腔形成,并减少早产儿视网膜病变大鼠模型中的视网膜前新生血管形成。通过抑制酪氨酸激酶活性减少血管生成可能是开发适用于眼部疾病的有效化疗方法的可行途径。